Spectrum Pharmaceuticals, Inc. Announces Publication Demonstrating Enhanced Survival With ZEVALIN in Premier Medical Journal Blood
Published: Jul 26, 2012
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today publication of positive long-term clinical data for ZEVALIN® (ibritumomab tiuxetan) Injection in patients with advanced, relapsed follicular non-Hodgkin’s lymphoma (fNHL). The data, published in Blood, the journal of the American Society of Hematology, showed that addition of ZEVALIN following fludarabine, cyclophosphamide, rituximab (FCR) conditioning and nonmyeloablative allogeneic stem cell transplantation (NST) resulted in a significantly improved 6-year overall survival (OS) estimate of 80% (95% CI, 41%-95%) in chemotherapy refractory patients, thereby overcoming a strong negative prognostic factor that typically precludes these patients from receiving other treatment options. As reported in the literature, following three episodes of relapsed disease, patients with chemorefractory disease have a median survival of 1.5 years.1 The clinical trial data were presented most recently at the 53rd American Society of Hematology Annual Meeting in December 2011.